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stry (201Abstract A new series of 3-substituted-2,1-benzisoxazoles (anthranils) were prepared by different
methods and characterized by spectroscopic methods and mass spectrometry. These 2,1-benzisox-
azoles were tested in vitro for their antiplasmodial activity on a chloroquine-resistant strain of
Plasmodium falciparum (P.f.) (FcB1), and for antimicrobial activity against representative bacterial
and fungal strains, as well as for cytotoxicity on MCF7 human breast cancer cells. Given the log
Pcalc and selectivity index values (cytotoxicity/antiplasmodial activity ratio), the benzo[c]isoxazol-
3-ylmethylene-phenyl-amine (11) (imino-benzisoxazole) was identiﬁed as the best hit against P.f.
(FcB1), and the benzo[c]isoxazol-3-yl-phenyl-methanone (3) (3-acyl-2,1-benzisoxazole) against
P.f. and the Geotrichum candidum fungal strain.
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3), http://dx.doi.org/10.1016/j.Benzisoxazoles (Boduszek et al., 1997; Sulikowski and Mak-
osza, 2009; Shelke et al., 2009; Chauhan and Fletcher, 2012)
are a promising class of heterocyclics which possess signiﬁcant
pharmacological and biological activities such as anticonvul-
sant (Stiff and Zemaitis, 1990), antimicrobial (Priya et al.,
2005), antipsychotic (Hrib et al., 2003), anticancer (Jain and
Kwon, 2003), and afﬁnity for serotonergic and dopaminergic
receptors (Nuhrich et al., 1996). In particular, 3-(N-benzyl-
piperidinylethyl)-1,2-benzisoxazoles inhibit acetyl cholinester-
ase, making them suitable candidates for the palliative
treatment of Alzheimer’s disease (Villalobos et al., 1994).
2,1-Benzisoxazoles (anthranils) are fused heteroaromatic sys-
tems applied as versatile synthons in ﬁne organic synthesis.
This is due to the easy ring opening at the labile N–O bond
and the ability of 2,1-benzisoxazoles to transform into othering Saud University.
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Figure 1 Structure of 3-substituted-2,1-benzisoxazoles 1–13.
Table 1 Structure, antiplasmodial and cytotoxic activities of 2,1-benzisoxazoles 1–12.
Compd. Structure M (g mol1)/Log Pcalc
a IC50 (lmol L
1) FcB1 CC50 (lmol L
1)b MCF7 Selectivity indexc MCF-7/FcB1
1
N
O
O OH 163.13/1.49 61.3 >613 >10
2
N
O
NH2
134.13/1.54 70.1 >480.5 >10
3
N
O
O
223.22/3.25 15.0 103 6.9
4
N
O
O Cl
257.67/3.75 12.8 50.5 3.9
5
N
O
O O
253.25/3.12 12.4 63.2 5.1
6
N
O
O
237.25/3.35 13.9 63 4.5
7
N
O
O HN 238.24/3.11 55.0 25.2 0.5
8
N
O
O N 218.25/2.28 130.6 155.8 1.2
9
N
O
O NH
O
268.26/3.08 69.9 37.3 0.53
10
N
O
O H 147.13/1.36 68.0 >680 >10
11
N
O
N 222.25/3.69 16.4 >450 >27.4
12
N
O
N
OO 342.35/3.59 >29.2 15.8 <0.54
Chloroquine 319/5.28 0.2 19.4 96
Sodium artesunate 406/2.29 0.006 9.8 1633
a Log Pcalc; calculated with VCCLAB (http://www.virtuallaboratory.org/lab/alogps/start.html).
b The drug concentration needed to cause a 50% decrease in cell viability; The IC50 SD were always lower than 20% and were discarded for
maximum lisibility.
c Cytotoxicity/antiplasmodial activity ratio.
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Figure 2 Structure of 2,1-benzisoxazole-3-carboxylic acid (1)
and 3-amino-2,1-benzisoxazole (2).
N
O
N
NH2
anhydrous MgSO4  / 
toluene
11
N
O
H
O
10
1) CDI, THF
2) NaBH4
3) MnO21
Scheme 2 Synthesis of the 2,1-benzisoxazole 11.
New 3-substituted-2,1-benzisoxazoles: Synthesis and antimicrobial activities 3heterocyclic systems, for instance, into acridinones (Ogata
et al., 1969). The acridinones are used extensively in the pro-
duction of dyes and pharmaceuticals (Ogata et al., 1969),
and also as biologically active compounds acting as anti-
inﬂammatory agents (Walsh, 1987) and glucohydrolase inhib-
itors (Farr and Peet, 1992). We were interested by the wide
variety of pharmacological properties of benzisoxazoles and
so we designed the synthesis of a new series of 3-substituted-
2,1-benzisoxazole in a continuing search for new alternative
drugs for malaria and infectious diseases (Nepveu et al.,
2010; Najahi et al., 2013). In this paper we report the antiplas-
modial and antimicrobial activities of a series of 3-substituted-
2,1-benzisoxazoles 1–13 (See Fig. 1).
2. Results and discussion
2.1. Chemistry
The series of 3-substituted-2,1-benzisoxazoles (anthranils)
(Table 1) were prepared from 2,1-benzisoxazole-3-carboxylic
acid 1 (Eckroth and Cochran, 1970) and 3-amino-2,1-benzis-
oxazole 2 (Musso and Schro¨der, 1965) (Fig. 2).
Different synthetic pathways were considered and success-
fully used in this work, which led to the desired 3-substi-
tuted-2,1-benzisoxazoles. Scheme 1 shows the synthesis of
anthranils starting from 2,1-benzisoxazole-3-carboxylic acid
1. The Friedel-Crafts reaction of the 2,1-benzisoxazole-3-car-
boxylic acid 1 with benzene or substituted benzene (chloroben-
zene, anisole or toluene) in dry benzene (96–98%) in the
presence of oxalyl chloride and aluminium chloride as catalystN
O
O
NH OMe
(COCl)2 / toluene
5
(COC
N
O
O
Cl
Cl
N
O
O
OCH3
3
4
9
(COCl)2 / AlCl3
1
(COCl)2 / AlCl3
(C
O
Cl
) 2
/ A
l C
l 3
N
O
O
OMe
H2N
Scheme 1 Synthesis of 3-substituted-2,1-benzisoxa
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Arabian Journal of Chemistry (2013), http://dx.doi.org/10.1016/j.yielded the expected 2,1-benzisoxazoles of type 3 (Benjamin
and Theodorus, 1993; Benjamin et al., 1991) or (4–6) in accept-
able yields (45–61%).
The 2,1-benzisoxazoles 7–9 were prepared starting from
compound 1 with aniline, diethylamine and 4-methoxyphenyl-
amine, respectively, in the presence of oxalyl chloride in anhy-
drous toluene in low yield (Scheme 1).
The reduction of the 2,1-benzisoxazole 1 via the benzylic
alcohol provided the anthranil 10 (Jackie et al., 2007), which
was transformed to the 3-imino-2,1-benzisoxazole 11 in an
acceptable yield by condensation with aniline (Scheme 2).
The 3-amino-2,1-benzisoxazole 2 condensed with benzyl
chloride in a solution of toluene and triethylamine gave the
anthranil 12 at a 22% yield. Approximately 7% of the com-
pound 2 was converted to the 2,1-benzisoxazole 13 as deter-
mined by 1H NMR of the crude material (Scheme 3).
The lipophilicity of the synthesized derivatives 1–12 was ex-
pressed in terms of their Log Pcalc values that were calculated
with the VCCLAB software. As shown in Table 1, higher Log
Pcalc values were observed for compounds 3–7 and 11–12
(3.11–3.69), compared to the 2,1-benzisoxazoles 1, 2 and 10
(1.36–1.49). For the former, the valueswere comparable to those
of the antimalarials sodium artesunate and of chloroquine.
2.2. Pharmacology
2.2.1. Antiplasmodial and cytotoxic activities
Antiplasmodial and cytotoxic activities were performed as pre-
viously described (Nepveu et al., 2010; Najahi et al., 2013). The(COCl)2 / toluene N
O
O
NHNH2
l)2 / toluene
HN
CH3
N
O
O CH3
8
6
7
(CO
Cl) 2
/ A
lCl 3
N
O
O
N
OCH3
zoles 3–9 starting from the 2,1-benzisoxazole 1.
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Scheme 3 Synthesis of 3-substituted-2,1-benzisoxazoles 12–13 starting from the 2,1-benzisoxazole 2.
Figure 3 Relationships between P.f. IC50 values (blue) and log Pcalc in the series (red).
4 A. Chaker et al.antiplasmodial activities of the 2,1-benzisoxazoles 1–12 ex-
pressed as the IC50 values, ranged between 12.4 and
130.6 lmol L1 (Table 1). The 2,1-benzisoxazole-3-carboxylic
acid 1 where R3‚COOH had the weakest activities with
IC50 values higher than 60 lmol L
1. Groups with higher lipo-
philicity (log P> 3) at position R3 (acyl/amide/imine) im-
proved the antiplasmodial activity (IC50/lmol L
1  12–16)
(3–6, 11) while groups (aldehyde) at R3 with lower lipophilicity
(log P< 3) led to a signiﬁcant decrease in the activity (IC50/
lmol L1: 10= 68). Fig. 3 illustrates the inverse relation be-
tween Log Pcalc and the IC50 values.
Cytotoxicity was assayed on the mammalian MCF7 cell
line and was higher than 15 lmol L1 with CC50 values rang-
ing from 15.8 to 680 lmol L1 (Table 1).Table 2 Antimicrobial activity of 2,1-benzisoxazoles.
Compound Pseudomonas
aeruginosa
Cronobacter
sakazakii
Bac
sub
MICa MIC MI
3 b b b
7 839.5 b b
12 584.2 b b
Tetracycline 56.5 17.9 71.
Ampicillin 71.9 14.3 14.
Amphotericinc b b b
a MICs: minimum inhibitory concentration (lmol L1).
b Inactive.
c Ref. (Sharma et al., 2011).
Please cite this article in press as: Chaker, A. et al., New 3-substitu
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The synthesized 2,1-benzisoxazoles 1–12 were evaluated for
their in vitro antibacterial activity against representative
Gram-positive (Bacillus subtilis, Staphylococcus aureus) and
Gram-negative bacteria (Pseudomonas aeruginosa, Cronobact-
er sakazakii) and against two fungi (Geotrichum candidum,
Candida albicans) using reported techniques (Najahi et al.,
2013). Minimum inhibitory concentrations (MICs) were calcu-
lated in order to express the antimicrobial activity and were de-
ﬁned as the concentration of the compound required to give
complete inhibition of the bacterial growth. From the 12 tested
compounds, only three presented antimicrobial activities.
Their MICs values are reported in Table 2 with those of refer-
ence drugs. The best activities were observed for compound 3illus
tilis
Staphylococcus
aureus
Geotrichum
candidum
Candida
albicans
C MIC MIC MIC
b 44.8 b
b b b
b b b
2 2.3 b b
5 0.6 b b
b 6.8 0.3
ted-2,1-benzisoxazoles: Synthesis and antimicrobial activities.
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New 3-substituted-2,1-benzisoxazoles: Synthesis and antimicrobial activities 5(MIC = 44.8 lmol L1) against G. candidum, and for com-
pounds 7 and 12 (MIC = 839.5 and 584.2 lmol L1,
respectively).
3. Conclusions
We report a new approach to the synthesis of 3-substituted-
2,1-benzisoxazoles starting from 2,1-benzisoxazole-3-carbox-
ylic acid and 3-amino-2,1-benzisoxazole. Although representa-
tives of this new series do not exhibit strong antimicrobial
activities, it should be noted that compound 11, with an IC50
value around the 10 lmolar level against P.f., had however
the best selectivity index in the series. This was achieved with-
out any substituent effect on either ring. Thus, there are actu-
ally opportunities of pharmaco-modulation for this compound
by introducing groups on both rings to try to reach an IC50 va-
lue in the nanomolar range and then multiplying the selectivity
index by a factor 103. Compounds 3–6 also showed interesting
antiplasmodial activities with an initial small pharmaco-modu-
lation effect of the substituent in the para position of the phe-
nyl ring. Working on both rings by introducing new
substituents may give good to very good antiplasmodial activ-
ities. Compound 3 gave a good result on G. candidum but other
similar derivatives (4–6) were inactive leaving little scope for
pharmacological modulation.
4. Experimental
4.1. General
Commercially available reagent grade chemicals were used as
received without additional puriﬁcation. All reactions were fol-
lowed by TLC (E. Merck Kieselgel 60 F-254), with detection
by UV light at 254 nm. Column chromatography was per-
formed on silica gel (60–200 mesh E. Merck). IR spectra were
recorded on a Perkin-Elmer PARAGON 1000 FT-IR spec-
trometer. 1H and 13C NMR spectra were recorded on an AC
Bruker spectrometer at 300 MHz (1H) and 75 MHz (13C) using
(CD3)2SO as solvent with (CD3)2SO (dH 2.5) or (CD3)2SO (dC
39.5). Chemical shifts (d) are reported in parts per million
(ppm) relative to tetramethylsilane (0 ppm). High-resolution
mass spectra (DCI in CH4) were recorded on a Bruker Maxis
spectrometer (Service Commun Toulouse, France). Melting
points were determined with an Electrothermal 9300 capillary
melting point apparatus and are uncorrected. The purity of all
compounds was determined by LC–PDA–MS methods and
was found to be in the range 96–99%.
4.2. Synthesis of 2,1-benzisoxazoles 3–6
This procedure was used for compounds 3–6. For example, for
compound 3 oxalyl chloride (m = 2.5 g, 20 mmol) was added
to benzisoxazole-3-carboxylic acid (0.150 g, 1 mmol) in dry
benzene (4 mL), and the reaction mixture was stirred at
80 C under a nitrogen atmosphere for 4 h. The solvent was
vacuum evaporated and the resultant residue dissolved in dry
benzene (4 mL), and AlCl3 (0.392 g, 2.94 mmol) was added
and the reaction mixture stirred at 80 C for 1 h. This reaction
mixture was then poured into ice-cold water and 37% aqueous
HCl and extracted with ethyl acetate (3 · 100 mL) and the
combined organic phase subsequently dried over anhydrousPlease cite this article in press as: Chaker, A. et al., New 3-substitu
Arabian Journal of Chemistry (2013), http://dx.doi.org/10.1016/j.MgSO4 and vacuum evaporated to afford the crude product.
This was further puriﬁed by column chromatography using
ethyl acetate-petroleum ether (v/v = 20/80) and recrystallized
from methanol-H2O (v/v = 60/40).
4.2.1. Benzo[c]isoxazol-3-yl-phenyl-methanone (3)
Yellow powder, yield: 49%, mp: 96–98 C. IR (KBr, cm1):
1651, 1627, 1189. 1H NMR (300 MHz, DMSO-d6) d: 8.14 (d,
J= 6 Hz, 2H), 7.98 (d, J= 9 Hz, 1H), 7.91 (d, J= 9 Hz,
1H), 7.76 (d, J= 7.5 Hz, 1H), 7.60 (m, 3H), 7.44 (d,
J= 7.8 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) d: 181.8
(C‚O), 157.3 (C), 154.3 (C), 136.3 (C), 134.4 (CH), 132.5
(CH), 130.2 (2CH), 129.6 (CH), 129.4 (2CH), 121.4 (CH),
121 (C), 116.2 (CH). HRMS (DCI, CH4) m/z calcd for
C14H10NO2 [M+H]
+ 224.0712. Found 224.0721.
4.2.2. Benzo[c]isoxazol-3-yl-(4-chloro-phenyl)-methanone (4)
Yellow powder, yield: 43%, mp: 127–129 C. IR (KBr, cm1):
1712, 1640, 1185, 753. 1H NMR (300 MHz, DMSO-d6) d: 8.20
(d, J= 8.4 Hz, 2H), 8.02 (d, J= 8.7 Hz, 1H), 7.93 (d,
J= 9 Hz, 1H), 7.76 (d, J= 8.7 Hz, 2H), 7.61 (dd,
J= 9.3 Hz, J= 5.4 Hz, 1H), 7.45 (dd, J= 8.7 Hz,
J= 6.6 Hz, 1H); 13C NMR (75 MHz, DMSO-d6): dC 180
(C‚O), 156.7 (C), 153.3 (C), 138.9 (C), 134.4 (C), 132.1
(CH), 131.6 (2CH), 129.2 (CH), 129 (2CH), 120.9 (CH),
120.6 (C), 115.7 (CH). HRMS (DCI, CH4) m/z calcd for
C14H9ClNO2 [M+H]
+ 258.0322. Found 258.0328.
4.2.3. Benzo[c]isoxazol-3-yl-(4-methoxy-phenyl)-methanone
(5)
Yellow powder, yield: 13%, mp: 125–127 C. IR (KBr, cm1):
1637, 1600, 1240, 1179. 1H NMR (300 MHz, DMSO-d6) d:
8.21 (d, J= 9 Hz, 2H), 8.01 (d, J= 8.4 Hz, 1H), 7.90 (d,
J= 9 Hz, 1H), 7.57 (dd, J= 9 Hz, J= 6 Hz, 1H), 7.41 (dd,
J= 8.7 Hz, J= 6.6 Hz, 1H), 7.21 (d, J= 9 Hz, 2H), 3.91 (s,
3H). HRMS (DCI, CH4) m/z calcd for C15H12NO3 [M+H]
+
254.0817. Found 254.0826.
4.2.4. Benzo[c]isoxazol-3-yl-p-tolyl-methanone (6)
White powder, yield: 9%, mp: 105–107 C. IR (KBr, cm1):
1647, 1617, 1235. 1H NMR (300 MHz, DMSO-d6) d: 8.10 (d,
J= 8.4 Hz, 2H), 8.00 (d, J= 8.7 Hz, 1H), 7.92 (d,
J= 9 Hz, 1H), 7.59 (dd, J= 9 Hz, J= 6.6 Hz, 1H), 7.44
(m, 3H), 2.46 (s, 3H). HRMS (DCI, CH4) m/z calcd for
C15H12NO2 [M+H]
+ 238.0868. Found 238.0875.
4.3. Synthesis of 2,1-benzisoxazoles 7–9
This procedure was used for compounds 7–9. For example, for
compound 7 oxalyl chloride (m = 2.5 g, 20 mmol) was added
to benzisoxazole-3-carboxylic acid (0.150 g, 0.919 mmol) in
dry toluene (4 mL), and the reaction mixture was stirred at
80 C under nitrogen for 16 h. The solvent was vacuum evap-
orated and the resultant residue dissolved in dry toluene
(2 mL). A solution of aniline (m = 0.207 g, 2.22 mmol) in
dry toluene (2 mL) was added drop-wise and the reaction mix-
ture was stirred at room temperature for 1 h. The mixture was
treated with aqueous HCl (1 M) and then extracted with ethyl
acetate (3 · 100 mL), and the combined organic phase
quenched with NaOH (1 M). Subsequently, the organic phaseted-2,1-benzisoxazoles: Synthesis and antimicrobial activities.
arabjc.2013.09.011
6 A. Chaker et al.was washed with brine (1 · 100 mL), dried over anhydrous
MgSO4, and evaporated in vacuum to afford the crude prod-
uct. This was further puriﬁed by column chromatography
using ethyl acetate-petroleum ether (v/v = 5/95).
4.3.1. Benzo[c]isoxazole-3-carboxylic acid phenylamide (7)
Yellow powder, yield: 39%, mp: 161–163 C. IR (KBr, cm1):
3270, 1676, 1617, 1152. 1H NMR (300 MHz, DMSO-d6) d:
11.12 (s, 1H, NH), 8.03 (d, J= 9 Hz, 1H), 7.85 (m, 3H),
7.55 (dd, J= 9 Hz, J= 6.3 Hz, 1H), 7.36 (m, 3H), 7.18 (m,
1H). 13C NMR (75 MHz, DMSO-d6) d: 157.5 (C‚O), 157.2
(C), 154.9 (C), 138.3 (C), 132.5 (CH), 129.2 (2CH), 127.2
(CH), 125.1 (CH), 121.3 (CH), 121.2 (2CH), 119.3 (C), 115.7
(CH). HRMS (DCI, CH4) m/z calcd for C14H11N2O2
[M+H]+ 239.0821. Found 239.0826.
4.3.2. Benzo[c]isoxazole-3-carboxylic acid diethylamide (8)
Yellow powder, yield: 34%, mp: 168–170 C. IR (KBr, cm1):
1672, 1612, 1151. 1H NMR (300 MHz, DMSO-d6) d: 7.83 (d,
J= 8.7 Hz, 1H), 7.74 (d, J= 8.4 Hz, 1H), 7.49 (dd, J= 9 Hz,
J= 6.3 Hz, 1H), 7.24 (dd, J= 8.7 Hz, J= 6.3 Hz, 1H), 3.56
(m, 4H), 1.23 (m, 6H). HRMS (DCI, CH4) m/z calcd for
C12H16N2O2 [M+H]
+ 219.1134. Found 219.1121.
4.3.3. Benzo[c]isoxazole-3-carboxylic acid (4-methoxy-
phenyl)-amide (9)
Yellow powder, yield: 27%, mp: 172–174 C. IR (KBr, cm1):
3335, 1672, 1629, 1206, 1189. 1H NMR (300 MHz, DMSO-d6)
d: 11.01 (s, 1H, NH), 8.02 (d, J= 9 Hz, 1H), 7.79 (m, 3H),
7.55 (dd, J= 9 Hz, J= 6.3 Hz, 1H), 7.43 (dd, J= 8.7 Hz,
6.6 Hz, 1H), 6.97 (d, J= 9 Hz, 2H), 3.76 (s, 3H). 13C NMR
(75 MHz, DMSO-d6) d: 157 (C‚O), 156.9 (C), 156.1 (C),
154.1 (C), 132 (CH), 130.8 (C), 127.2 (CH), 122.2 (2CH),
120.9 (CH), 118.7 (C), 115.1 (CH), 113.8 (2CH), 55.2
(OCH3). HRMS (DCI, CH4) m/z calcd for C15H13N2O3
[M+H]+ 269.0926. Found 269.0921.
4.4. Benzo[c]isoxazol-3-ylmethylene-phenyl-amine (11)
2,1-Benzisoxazole-3-carbaldehyde (10) (0.08 g, 0.543 mmol),
prepared according to the literature [16], was added to a vigor-
ously stirring solution of aniline (0.051 g, 0.547 mmol) and
anhydrous MgSO4 (0.262 g, 2.175 mmol) in dry toluene
(1 mL) under a nitrogen atmosphere at 0–5 C. The reaction
mixture was stirred for an additional 15 min at 0–5 C. The
heterogeneous mixture was stirred vigorously for 4 h at room
temperature, at which point it cleared and TLC analysis indi-
cated complete consumption of the reactants. The mixture was
ﬁltered and the ﬁltrate was evaporated in a vacuum to afford a
yellow oil. This was further puriﬁed by column chromatogra-
phy using ethyl acetate-petroleum ether (3:97). Yellow oil,
yield: 63%. 1H NMR (300 MHz, DMSO-d6) d: 9.19 (s, 1H,
HC‚N), 8.20 (d, J= 8.7 Hz, 1H), 7.80 (d, J= 9 Hz, 1H),
7.53 (m, 5H), 7.36 (m, 2H). HRMS (DCI, CH4) m/z calcd
for C14H11N2O [M+H]
+ 223.0871. Found 223.0887.
4.5. N-Benzo[c]isoxazol-3-yl-N-benzoyl-benzamide (12)
Et3N (0.045 g, 0.447 mmol) was added to 3-amino-2,1-benzis-
oxazole (m = 0.060 g, 0.447 mmol) in dry toluene (6 mL), andPlease cite this article in press as: Chaker, A. et al., New 3-substitu
Arabian Journal of Chemistry (2013), http://dx.doi.org/10.1016/j.stirred at 0–5 C for 10 min and then benzoyl chloride (0.069 g,
0.492 mmol) was added drop-wise. The reaction mixture was
then stirred at 0–5 C for 2 h. The mixture was treated with
5% aqueous HCl (1 · 10 mL) and then extracted with ethyl
acetate (3 · 25 mL), and the combined organic phase quenched
with aqueous NaHCO3 (1 · 25 mL). The organic phase was
subsequently washed with brine (1 · 25 mL), dried over anhy-
drous MgSO4, and vacuum evaporated to afford the crude
product. This was further puriﬁed by column chromatography
using toluene-acetone (v/v = 80/20). Yellow powder, yield:
22%, mp: 105.4 C. IR (KBr, cm1): 1683, 1630, 1447, 1190.
1H NMR (300 MHz, DMSO-d6) d: 8.01 (m, 3H), 7.78 (m,
3H), 7.91 (m, 5H), 7.51 (d, J= 6 Hz, 1H), 7.44 (m, 2H).
HRMS (DCI, CH4) m/z calcd for C21H15N2O3 [M+H]
+
343.1083. Found 343.1097.
4.6. Methodology for in vitro biological evaluation
4.6.1. In vitro antiplasmodial and cytotoxicity assays
The in vitro antipalasmodial assay was carried out against the
chloroquine-resistant strain (FcB1) of Plasmodium falciparum
and the in vitro cytotoxicity was determined on human breast
cancer cells (MCF7) (Cachet et al., 2009; Ribaut et al., 2008).
All these assays were performed as previously reported (Nep-
veu et al., 2010; Najahi et al., 2013) and details are given in
the supplementary data.4.6.2. Antimicrobial assays
All microorganisms were grown in broth medium with
continuous shaking (200 rpm). Bacillus subtilis (CIP 5262),
Staphylococcus aureus (CIP 53156) were used as Gram-positive
strains. The Gram-negative strains used were Pseudomonas
aeruginosa (CIP 82118), Cronobacter sakazakii (CIP 103183).
Fungal strains used were Candida albicans (CIP 4872) and
Geotricum candidum (ATCC 204307). The minimal inhibitory
concentrations (MICs) were performed as previously reported
(Najahi et al., 2013) and details are given in the supplementary
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